Bernhard Hoffmann - 28 Jan 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role
VP of Corp. Dev. & Ops & Sec.
Signature
/s/ Jeffrey Kuras, by Power of Attorney
Issuer symbol
IRD
Transactions as of
28 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 15:29:46 UTC
Next filing
12 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUP Employee Stock Option (right to buy) Award $0 +42,500 $0.000000 42,500 28 Jan 2022 Common Stock 42,500 $2.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest with respect to 10,625 shares on January 28, 2023, and then with respect to 885 shares on the last day of each month from February 2023 through December 2025 and with respect to 900 shares at the end of January 2026.